Fig. 2: Cisplatin resistance predicts palbociclib resistance in mice bearing HNSCC cell-line-derived xenografts.

Tumor growth curves of paired cisplatin-sensitive (a, c, e) and cisplatin-resistant (b, d, f) HNSCC cell lines, treated for 10 days with palbociclib (70 mg/kg, daily). N = 5 mice per group and measurements are summarized as mean ± SEM. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test)